WO2001089526A1 - Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation - Google Patents

Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation Download PDF

Info

Publication number
WO2001089526A1
WO2001089526A1 PCT/US2001/015708 US0115708W WO0189526A1 WO 2001089526 A1 WO2001089526 A1 WO 2001089526A1 US 0115708 W US0115708 W US 0115708W WO 0189526 A1 WO0189526 A1 WO 0189526A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
vagus nerve
syndrome
stimulated
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/015708
Other languages
English (en)
French (fr)
Inventor
Kevin J. Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
North Shore Long Island Jewish Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Shore Long Island Jewish Research Institute filed Critical North Shore Long Island Jewish Research Institute
Priority to JP2001585770A priority Critical patent/JP2004510695A/ja
Priority to CA2408791A priority patent/CA2408791C/en
Priority to AU2001261629A priority patent/AU2001261629B2/en
Priority to AU6162901A priority patent/AU6162901A/xx
Priority to EP01935542A priority patent/EP1307196A4/en
Publication of WO2001089526A1 publication Critical patent/WO2001089526A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention generally relates to methods of reducing inflammation. More specifically, the invention relates to methods for reducing inflammation caused by proinflammatory cytokines or an inflammatory cytokine cascade.
  • Vertebrates achieve internal homeostasis during infection or injury by balancing the activities of proinflammatory and anti-inflammatory pathways. However, in many disease conditions, this internal homeostasis becomes out of balance. For example, endotoxin (lipopol saccharide, LPS) produced by all Gram-negative bacteria activates macrophages to release cytokines that are potentially lethal (44; 10; 47; 31).
  • endotoxin lipopol saccharide, LPS
  • Inflammation and other deleterious conditions are often induced by proinflammatory cytokines, such as tumor necrosis factor (TNF; also known as TNF ⁇ or cachectin), interleukin (IL)-l ⁇ , IL-l ⁇ , IL-6, IL-8, IL-18, interferon ⁇ , platelet-activating factor (PAF), macrophage migration inhibitory factor (MIF), and other compounds (42).
  • TNF tumor necrosis factor
  • IL-l ⁇ interleukin
  • IL-6 interleukin-l ⁇
  • IL-8 interleukin-8
  • IL-18 interferon ⁇
  • PAF platelet-activating factor
  • MIF macrophage migration inhibitory factor
  • HMG-1 high mobility group protein 1
  • proinflammatory cytokines are produced by several different cell types, most importantly immune cells (for example monocytes, macrophages and neutrophils), but also non- immune cells such as fibroblasts, osteoblasts, smooth muscle cells, epithelial cells, and neurons (56). Proinflammatory cytokines contribute to various cell types, most importantly immune cells (for example monocytes, macrophages and neutrophils), but also non- immune cells such as fibroblasts, osteoblasts, smooth muscle cells, epithelial cells, and neurons (56). Proinflammatory cytokines contribute to various cell types, most importantly immune cells (for example monocytes, macrophages and neutrophils), but also non- immune cells such as fibroblasts, osteoblasts, smooth muscle cells, epithelial cells, and neurons (56). Proinflammatory cytokines contribute to various cell types, most importantly immune cells (for example monocytes, macrophages and neutrophils), but also non- immune cells such as fibroblasts, osteoblasts, smooth muscle cells, epithelial cells, and
  • 164029.1 disorders notably sepsis, through their release during an inflammatory cytokine cascade.
  • Inflammatory cytokine cascades contribute to deleterious characteristics, including inflammation and apoptosis (32), of numerous disorders. Included are disorders characterized by both localized and systemic reactions, including, without limitation, diseases involving the gastrointestinal tract and associated tissues (such as appendicitis, peptic, gastric and duodenal ulcers, peritonitis, pancreatitis, ulcerative, pseudomembranous, acute and ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, coeliac disease, cholecystitis, hepatitis, Crohn's disease, enteritis, and Whipple's disease); systemic or local inflammatory diseases and conditions (such as asthma, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granulo
  • 164029.1 disease meningitis, encephalitis, multiple sclerosis, cerebral infarction, cerebral embolism, Guillame-Barre syndrome, neuritis, neuralgia, spinal cord injury, paralysis, and uveitis); diseases of the bones, joints, muscles and connective tissues (such as the various arthritides and arthralgias, osteomyelitis, fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, and synovitis); other autoimmune and inflammatory disorders (such as myasthenia gravis, thryoiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcets's syndrome, allograft rejection, graft-versus-host disease, Type I diabetes, ankylosing spondylitis, Berger's disease, Type I diabetes, ankylosing spondylitis, Berger's disease, and Retier's syndrome); as well as
  • Mammals respond to inflammation caused by inflammatory cytokine cascades in part though central nervous system regulation. This response has been characterized in detail with respect to systemic humoral response mechanisms during inflammatory responses to endotoxin (2; 54; 21; 28).
  • afferent vagus nerve fibers are activated by endotoxin or cytokines, stimulating the release of humoral anti-inflammatory responses through glucocorticoid hormone release (51; 41; 39).
  • Previous work elucidated a role for vagus nerve signaling as a critical component in the afferent loop that modulates the adrenocorticotropin and fever responses to systemic endotoxemia and cytokinemia (14; 11; 52; 35).
  • cholinergic agonists can inhibit the release of proinflammatory cytokines from a mammalian cell, either in vitro or in vivo. This inhibitory effect is useful for inhibiting inflammatory cytokine cascades that mediate many disease conditions. Furthermore, cholinergic agonist treatment in vivo can be effected to inhibit either local or systemic inflammatory cytokine cascades by stimulating efferent vagus nerves.
  • one embodiment of the present invention is directed to a method of inhibiting the release of a proinflammatory cytokine from a mammalian cell.
  • the method comprises treating the cell with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the cell.
  • the cell is a macrophage.
  • the proinflammatory cytokine is tumor necrosis factor (TNF), interleukin (IL)-l ⁇ , IL-6, IL-18 or HMG-1, most preferably TNF.
  • the cholinergic agonist is acetylcholine, nicotine, muscarine, carbachol, galantamine, arecoline, cevimeline, or levamisole.
  • the cell is in a patient suffering from, or at risk for, a condition mediated by an inflammatory cytokine cascade, preferably appendicitis, peptic, gastric or duodenal ulcers, peritonitis, pancreatitis, ulcerative, pseudomembranous, acute or ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, Crohn's disease, enteritis, Whipple's disease, asthma, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, hyperpyrexia, eosinophilic granuloma,
  • an inflammatory cytokine cascade preferably appendicitis, peptic, gastric or duodenal ulcers, peritonitis, pancreatitis, ulcerative,
  • 164029.1 granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, cystic fibrosis, pneumonitis, pneumoultramicroscopicsilicovolcanoconiosis, alvealitis, bronchiolitis, pharyngitis, pleurisy, sinusitis, influenza, respiratory syncytial virus infection, herpes infection, HIV infection, hepatitis B virus infection, hepatitis C virus infection, disseminated bacteremia, Dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid cysts, burns, dermatitis, dermatomyositis, sunburn, urticaria, warts, wheals, vasulitis, angiitis, endocarditis
  • the condition is appendicitis, peptic, gastric or duodenal ulcers, peritonitis, pancreatitis, ulcerative, pseudomembranous, acute or ischemic colitis, hepatitis, Crohn's disease, asthma, allergy, anaphylactic shock, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, septic abortion, disseminated bacteremia, burns, Alzheimer's disease, coeliac disease, congestive heart failure, adult respiratory distress syndrome, cerebral infarction, cerebral embolism, spinal cord injury, paralysis, allograft rejection or graft-versus-host disease.
  • the condition is endotoxic shock.
  • the cholinergic agonist treatment is effected by stimulating efferent vagus nerve activity sufficient to inhibit the inflammatory cytokine cascade.
  • the cholinergic agonist treatment is effected by stimulating efferent vagus nerve activity
  • efferent vagus nerve activity is stimulated electrically.
  • the efferent vagus nerve can be stimulated without stimulating the afferent vagus nerve.
  • Vagus nerve ganglions or postganglionic neurons can also be stimulated. Additionally, peripheral tissues or organs that are served by the vagus nerve can also be stimulated directly.
  • the present invention is also directed to a method of inhibiting an inflammatory cytokine cascade in a patient.
  • the method comprises treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the patient is suffering from, or at risk for, a condition mediated by the inflammatory cytokine cascade.
  • the cholinergic agonist is preferably acetylcholine, nicotine, muscarine, carbachol, galantamine, arecoline, cevimeline, or levamisole, and the condition is preferably appendicitis, peptic, gastric or duodenal ulcers, peritonitis, pancreatitis, ulcerative, pseudomembranous, acute or ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, Crohn's disease, enteritis, Whipple's disease, asthma, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, byperpyrexia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, va
  • 164029.1 infarction, cerebral embolism, Guillame-Barre syndrome, neuritis, neuralgia, spinal cord injury, paralysis, uveitis, arthritides, arthralgias, osteomyelitis, fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, synovitis, myasthenia gravis, thryoiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcets's syndrome, allograft rejection, graft-versus- host disease, Type I diabetes, ankylosing spondylitis, Berger's disease, Type I diabetes, ankylosing spondylitis, Berger's disease, Retier's syndrome, or Hodgkins disease.
  • the condition is appendicitis, peptic, gastric or duodenal ulcers, peritonitis, pancreatitis, ulcerative, pseudomembranous, acute or ischemic colitis, hepatitis, Crohn's disease, asthma, allergy, anaphylactic shock, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, septicemia, endotoxic shock, cachexia, septic abortion, disseminated bacteremia, burns, Alzheimer's disease, coeliac disease, congestive heart failure, adult respiratory distress syndrome, cerebral infarction, cerebral embolism, spinal cord injury, paralysis, allograft rejection or graft- versus-host disease.
  • the condition is endotoxic shock.
  • the cholinergic agonist treatment can be effected by stimulating efferent vagus nerve activity, preferably electrically.
  • the present invention is directed to a method for treating a patient suffering from, or at risk for, a condition mediated by an inflammatory cytokine cascade.
  • the method comprises stimulating efferent vagus nerve activity of the patient sufficient to inhibit the inflammatory cytokine cascade. Preferred methods of stimulation and preferred conditions are as with the previously described methods.
  • the present invention is directed to a method for attenuation of a systemic inflammatory response to endotoxin in a patient. The method comprises stimulating efferent vagus nerve activity of the patient sufficient to inhibit an inflammatory cytokine cascade.
  • the present invention is additionally directed to a method for determining whether a compound is a cholinergic agonist.
  • the method is additionally directed to a method for determining whether a compound is a cholinergic agonist.
  • 164029.1 comprises determining whether the compound inhibits the release of a proinflammatory cytokine from a mammalian cell.
  • the cell is a macrophage and the proinflammatory cytokine is TNF.
  • Figure 1 is a graph summarizing experimental results showing that cholinergic agonists inhibit release of TNF from human macrophage cultures in a dose-dependent manner.
  • Acetylcholine (ACh), muscarine, or nicotine was added to human macrophage cultures at the concentrations indicated, followed by LPS addition for 4 hours. TNF concentration was then determined.
  • Figure 2 shows autoradiographs of TNF or GADPH mRNA from LPS- stimulated human macrophages treated with acetylcholine (ACh), nicotine (Nic) or muscarine (Mus), or no cholinergic agonist, which demonstrate that cholinergic agonists do not reduce LPS-stimulated TNF mRNA levels in macrophages.
  • Figure 3 shows micrographs of human macrophages stained with TNF antibodies demonstrating the effect of LPS and/or acetylcholine (ACh) treatment on TNF presence in the cells.
  • Figure 4 is a graph summarizing experimental results showing that 06- conotoxin ( ⁇ -CTX), but not atropine (ATR), reverses the inhibitory effect of acetylcholine (ACh) -mediated inhibition of TNF in human macrophages.
  • Figure 5 is a graph summarizing experimental results showing that acetylcholine inhibits IL-l ⁇ release from human macrophages in a dose- dependent manner.
  • Figure 6 is a graph summarizing experimental results showing that acetylcholine inhibits IL-6 release from human macrophages in a dose-dependent manner.
  • Figure 7 is a graph summarizing experimental results showing that acetylcholine inhibits IL-18 release from human macrophages in a dose-dependent manner.
  • Figure 8 is a graph summarizing experimental results showing that acetylcholine does not inhibit IL-10 release from human macrophages.
  • FIG. 9 is a graph summarizing experimental results showing that vagus nerve stimulation (STIM) after vagotomy (VGX) causes a decrease in circulating levels of TNF during endotoxemia induced by LPS.
  • STIM vagus nerve stimulation
  • VGX vagotomy
  • FIG 10 is a graph summarizing experimental results showing that vagus nerve stimulation (STIM) after vagotomy (VGX) causes a decrease in levels of TNF in the liver during endotoxemia induced by LPS.
  • STIM vagus nerve stimulation
  • VGX vagotomy
  • FIG 11 is a graph summarizing experimental results showing that vagus nerve stimulation (STIM) after vagotomy (VGX) attenuates the development of hypotension (shock), as measured by mean arterial blood pressure (MABP), in rats exposed to lethal doses of endotoxin.
  • STIM vagus nerve stimulation
  • VGX vagotomy
  • MABP mean arterial blood pressure
  • Figure 12 is a graph summarizing experimental results showing that intact vagus nerve stimulation at IV and 5V attenuates the development of shock in rats exposed to lethal doses of endotoxin.
  • Figure 13 is a graph summarizing experimental results showing that intact vagus nerve stimulation at IV and 5V causes an increase in heart rate in rats exposed to lethal doses of endotoxin.
  • Figure 14 is a graph summarizing experimental results showing that intact left vagus nerve stimulation at IV stabilized blood pressure more effectively than intact right vagus nerve stimulation, in rats exposed to lethal doses of endotoxin.
  • Figure 15 is a western blot and graph of experimental results showing that addition of nicotine to RAW 264.7 macrophage-like cells inhibits the production of HMG-1 by the cells.
  • the present invention is based on the discovery that treatment of a proinflammatory cytokine-producing cell with a cholinergic agonist attenuates the release of proinflammatory cytokines from that cell, and that this attenuation process can be utilized in treatments for disorders mediated by an inflammatory cytokine cascade (5-6). It has further been discovered that stimulation of efferent vagus nerve fibers releases sufficient acetylcholine to stop a systemic inflammatory cytokine cascade, as occurs in endotoxic shock (5), or a localized inflammatory cytokine cascade (6). The efferent vagus nerve stimulation can also inhibit a localized inflammatory cytokine cascade in tissues and organs that are served by efferent vagus nerve fibers.
  • the present invention is directed to methods of inhibiting the release of a proinflammatory cytokine from a mammalian cell.
  • the methods comprise treating the cell with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine released from the cell.
  • a cytokine is a soluble protein or peptide which is naturally produced by mammalian cells and which act in vivo as humoral regulators at micro- to picomolar concentrations. Cytokines can, either under normal or pathological conditions, modulate the functional activities of individual cells and tissues.
  • a proinflammatory cytokine is a cytokine that is capable of causing any of the following physiological reactions associated with inflammation: vasodialation, hyperemia, increased permeability of vessels with associated edema, accumulation of granulocytes and mononuclear phagocytes, or deposition of fibrin. In some cases, the proinflammatory cytokine can also
  • a mammalian cell that produces proinflammatory cytokines are useful for the practice of the invention.
  • Nonlimiting examples are monocytes, macrophages, neutrophils, epithelial cells, osteoblasts, fibroblasts, smooth muscle cells, and neurons.
  • the cell is a macrophage.
  • a cholinergic agonist is a compound that binds to cells expressing cholinergic receptor activity. The skilled artisan can determine whether any particular compound is a cholinergic agonist by any of several well known methods.
  • the use of the terms "inhibit” or “decrease” encompasses at least a small but measurable reduction in proinflammatory cytokine release.
  • the release of the proinflammatory cytokine is inhibited by at least 20% over non- treated controls; in more preferred embodiments, the inhibition is at least 50%; in still more preferred embodiments, the inhibition is at least 70%, and in the most preferred embodiments, the inhibition is at least 80%.
  • Such reductions in proinflammatory cytokine release are capable of reducing the deleterious effects of an inflammatory cytokine cascade in in vivo embodiments.
  • the present invention is useful for studying cells in culture, for example studying the effect of inflammatory cytokine release on the biology of macrophages, or for testing compounds for cholinergic agonist activity.
  • the present invention includes nasally administering to the mammal a therapeutically effective amount of the cholinergic agonist.
  • nasally administering or nasal administration includes administering the cholinergic agonist to the mucous membranes of the nasal passage or nasal cavity of the patient.
  • pharmaceutical compositions for nasal administration of a cholinergic agonist include therapeutically effective amounts of the agonist prepared by well-known methods to be administered, for example, as a nasal spray, nasal drop, suspension, gel, ointment, cream or powder. Administration of the cholinergic agonist may also take place using a nasal tampon or nasal sponge.
  • MCSF macrophage colony stimulating factor
  • 164029*1 cholinergic agonists as compared to peripheral blood mononuclear cells.
  • the skilled artisan would not necessarily have expected macrophages to be so sensitive to cholinergic agonists, or even have any sensitivity at all, given what was previously known with mononuclear cells. Indeed, recent evidence in our lab has revealed nicotinic receptor subunit expression patterns in macrophages that are distinct from monocytes. Therefore, the skilled artisan would understand that molecular differences underlie the greater sensitivity to cholinergic agonists of macrophages over monocytes.
  • FIG 13 shows the heart rate of the experimental animals. Within minutes after LPS injection, the heart rate began to increase in rats stimulated with a high dose (5V) of vagus nerve stimulation. On the other hand, the heart rates of both unstimulated rats and rats stimulated with a low dose (IV) of voltage remained stable for approximately 60 min. post-LPS. After one hour, the heart rates of the rats treated with a low dose of stimulation began to increase, and reached levels comparable to those rats receiving a high dose of vagus nerve stimulation.
  • Figure 14 compares left vs. right vagus nerve stimulation. Endotoxic animals were treated with IV stimulation in either the left or the right vagus nerve.
  • Murine RAW 264.7 macrophage-like cells (American Type Culture Collection, Rockville, MD, USA) were grown in culture under DMEM supplemented with 10% fetal bovine serum and 1% glutamine. When the cells were 70-80% confluent, the medium was replaced by serum-free OPTI-MEM I medium. Nicotine (Sigma) was then added at 0, 0.1, 1, 10 or 100 ⁇ M. Five minutes after adding the nicotine, the cultures were treated with LPS (500 ng/ml). Culture medium was collected after 20 hr.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
PCT/US2001/015708 2000-05-23 2001-05-16 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation Ceased WO2001089526A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001585770A JP2004510695A (ja) 2000-05-23 2001-05-16 コリン作動薬および迷走神経刺激による炎症性サイトカイン産生の阻害
CA2408791A CA2408791C (en) 2000-05-23 2001-05-16 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
AU2001261629A AU2001261629B2 (en) 2000-05-23 2001-05-16 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
AU6162901A AU6162901A (en) 2000-05-23 2001-05-16 Inhibition of inflammatory cytokine production by cholinergic agonists and vagusnerve stimulation
EP01935542A EP1307196A4 (en) 2000-05-23 2001-05-16 INHIBITION OF THE PRODUCTION OF INFLAMMABLE CYTOKINS BY CHOLINER AGONISTS AND THE STIMULATION OF NERVUS VAGUS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20636400P 2000-05-23 2000-05-23
US60/206,364 2000-05-23
US09/855,446 2001-05-15
US09/855,446 US6610713B2 (en) 2000-05-23 2001-05-15 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation

Publications (1)

Publication Number Publication Date
WO2001089526A1 true WO2001089526A1 (en) 2001-11-29

Family

ID=26901277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015708 Ceased WO2001089526A1 (en) 2000-05-23 2001-05-16 Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation

Country Status (6)

Country Link
US (2) US6610713B2 (https=)
EP (1) EP1307196A4 (https=)
JP (1) JP2004510695A (https=)
AU (2) AU6162901A (https=)
CA (1) CA2408791C (https=)
WO (1) WO2001089526A1 (https=)

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
WO2004004763A3 (en) * 2002-07-03 2004-02-26 San Raffaele Centro Fond Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2003072135A3 (en) * 2002-02-26 2004-07-22 Long Island Jewish Res Inst Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
WO2005072713A3 (en) * 2004-01-27 2005-12-08 Long Island Jewish Res Inst Cholinesterase inhibitors for treating inflammation
US7184829B2 (en) 1996-04-30 2007-02-27 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
US7184828B2 (en) 2000-09-26 2007-02-27 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US7269457B2 (en) 1996-04-30 2007-09-11 Medtronic, Inc. Method and system for vagal nerve stimulation with multi-site cardiac pacing
US7310552B2 (en) 1997-08-26 2007-12-18 Puskas John D Apparatus for indirectly stimulating the vagus nerve with an electrical field
US7418292B2 (en) 2003-10-01 2008-08-26 Medtronic, Inc. Device and method for attenuating an immune response
EP1949901A3 (en) * 2002-12-06 2008-10-15 The Feinstein Institute for Medical Research Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
EP1948301A4 (en) * 2005-11-10 2009-10-14 Electrocore Inc TREATMENT OF BRONCHIC CONSTRICTION BY ELECTRICAL STIMULATION
US7668602B2 (en) 2003-06-13 2010-02-23 Bio Control Medical (B.C.M.) Ltd. Minimal-heart-rate reduction parasympathetic stimulation
US7711430B2 (en) 2006-02-10 2010-05-04 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US7725188B2 (en) 2006-02-10 2010-05-25 Electrocore Llc Electrical stimulation treatment of hypotension
US7785808B2 (en) 2002-12-06 2010-08-31 The Feinstein Institute For Medical Research Treatment of inflammation using α7 receptor-binding cholinergic agonists
US8036741B2 (en) 1996-04-30 2011-10-11 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US8406868B2 (en) 2010-04-29 2013-03-26 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US8524866B2 (en) 2005-11-15 2013-09-03 The Feinstein Institute For Medical Research Antibodies to the alpha-7 nicotinic receptors and methods of treating inflammatory disorders with the same
US8612002B2 (en) 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US8731663B2 (en) 2009-07-01 2014-05-20 Medtronic, Inc. Vagal stimulation during atrial tachyarrhythmia to facilitate cardiac resynchronization therapy
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8812112B2 (en) 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US8840537B2 (en) 2005-11-10 2014-09-23 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8932289B2 (en) 2009-10-27 2015-01-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8961507B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
EP2801359A3 (en) * 2006-05-08 2015-05-06 Arturo Solis Herrera The use of nicotine for the treatment of sepsis in humans caused by antibiotic
US9079031B2 (en) 2008-09-11 2015-07-14 Trifectas Medical Corp. Method for improving functional recovery after stroke by electrical stimulation of a cranial nerve
US9125643B2 (en) 2008-02-15 2015-09-08 Holaira, Inc. System and method for bronchial dilation
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9339618B2 (en) 2003-05-13 2016-05-17 Holaira, Inc. Method and apparatus for controlling narrowing of at least one airway
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9668969B1 (en) 2012-02-22 2017-06-06 Arturo Solis Herrera Methods of using QIAPINE
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
CN110035754A (zh) * 2016-06-29 2019-07-19 图拉维治疗股份有限公司 通过自主神经系统的局部神经调节治疗败血症及相关炎性病况
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
EP3768261A1 (en) * 2018-03-22 2021-01-27 NSC THERAPEUTICS GmbH Compounds and methods for use in the treatment of microglia-mediated disorders
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US11246879B2 (en) 2016-02-09 2022-02-15 Tulai Therapeutics, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11344724B2 (en) 2004-12-27 2022-05-31 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US11446359B2 (en) 2015-04-27 2022-09-20 Tulavi Therapeutics, Inc. Systems and methods for cardiac plexus neuromodulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US11890393B2 (en) 2018-07-02 2024-02-06 Tulavi Therapeutics, Inc. Methods and devices for in situ formed nerve cap
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12096941B2 (en) 2018-07-02 2024-09-24 Tulavi Therapeutics, Inc. Methods for forming a nerve barrier
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US12533531B2 (en) 2020-01-13 2026-01-27 The Feinstein Institutes For Medical Research Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
US12582819B2 (en) 2022-01-20 2026-03-24 Setpoint Medical Corporation Treatment of inflammatory disorders

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6587719B1 (en) 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
US20070203531A9 (en) * 1999-12-03 2007-08-30 Medtronic, Inc. Heart rate variability control of gastric electrical stimulator
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6609025B2 (en) 2001-01-02 2003-08-19 Cyberonics, Inc. Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US6684105B2 (en) 2001-08-31 2004-01-27 Biocontrol Medical, Ltd. Treatment of disorders by unidirectional nerve stimulation
US6907295B2 (en) 2001-08-31 2005-06-14 Biocontrol Medical Ltd. Electrode assembly for nerve control
US8571653B2 (en) 2001-08-31 2013-10-29 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US7904176B2 (en) 2006-09-07 2011-03-08 Bio Control Medical (B.C.M.) Ltd. Techniques for reducing pain associated with nerve stimulation
US7885709B2 (en) 2001-08-31 2011-02-08 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation for treating disorders
US7778703B2 (en) * 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Selective nerve fiber stimulation for treating heart conditions
US7778711B2 (en) 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US7974693B2 (en) 2001-08-31 2011-07-05 Bio Control Medical (B.C.M.) Ltd. Techniques for applying, configuring, and coordinating nerve fiber stimulation
US7734355B2 (en) * 2001-08-31 2010-06-08 Bio Control Medical (B.C.M.) Ltd. Treatment of disorders by unidirectional nerve stimulation
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US7844346B2 (en) 2002-05-23 2010-11-30 Biocontrol Medical Ltd. Electrode assembly for nerve control
US8204591B2 (en) 2002-05-23 2012-06-19 Bio Control Medical (B.C.M.) Ltd. Techniques for prevention of atrial fibrillation
US7321793B2 (en) * 2003-06-13 2008-01-22 Biocontrol Medical Ltd. Vagal stimulation for atrial fibrillation therapy
US7561922B2 (en) 2004-12-22 2009-07-14 Biocontrol Medical Ltd. Construction of electrode assembly for nerve control
US8880192B2 (en) 2012-04-02 2014-11-04 Bio Control Medical (B.C.M.) Ltd. Electrode cuffs
US7627384B2 (en) 2004-11-15 2009-12-01 Bio Control Medical (B.C.M.) Ltd. Techniques for nerve stimulation
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US20040172084A1 (en) 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US7444183B2 (en) * 2003-02-03 2008-10-28 Enteromedics, Inc. Intraluminal electrode apparatus and method
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
CN1964630A (zh) * 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
US8060197B2 (en) * 2003-05-23 2011-11-15 Bio Control Medical (B.C.M.) Ltd. Parasympathetic stimulation for termination of non-sinus atrial tachycardia
US7738952B2 (en) 2003-06-09 2010-06-15 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system
EP1648560A4 (en) 2003-06-13 2015-10-28 Biocontrol Medical Ltd VAGAL STIMULATION FOR ANTI-EMBOLIC THERAPY
US20050075702A1 (en) * 2003-10-01 2005-04-07 Medtronic, Inc. Device and method for inhibiting release of pro-inflammatory mediator
WO2005041979A1 (en) * 2003-10-30 2005-05-12 University Of South Florida Modulation of microglial by nicotinic medications
US7657312B2 (en) 2003-11-03 2010-02-02 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US9050469B1 (en) 2003-11-26 2015-06-09 Flint Hills Scientific, Llc Method and system for logging quantitative seizure information and assessing efficacy of therapy using cardiac signals
US7783353B2 (en) 2003-12-24 2010-08-24 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on activity and circadian rhythm
US8200331B2 (en) 2004-11-04 2012-06-12 Cardiac Pacemakers, Inc. System and method for filtering neural stimulation
US7647114B2 (en) 2003-12-24 2010-01-12 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US20050149132A1 (en) 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation based on cardiac activity
US7869881B2 (en) * 2003-12-24 2011-01-11 Cardiac Pacemakers, Inc. Baroreflex stimulator with integrated pressure sensor
US7668594B2 (en) * 2005-08-19 2010-02-23 Cardiac Pacemakers, Inc. Method and apparatus for delivering chronic and post-ischemia cardiac therapies
US8126560B2 (en) 2003-12-24 2012-02-28 Cardiac Pacemakers, Inc. Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US7643875B2 (en) 2003-12-24 2010-01-05 Cardiac Pacemakers, Inc. Baroreflex stimulation system to reduce hypertension
WO2006007048A2 (en) * 2004-05-04 2006-01-19 The Cleveland Clinic Foundation Methods of treating medical conditions by neuromodulation of the sympathetic nervous system
DK1759536T3 (da) 2004-06-01 2011-09-05 Kwalata Trading Ltd In vitro-teknikker til anvendelse med stamceller
WO2005117860A1 (en) * 2004-06-03 2005-12-15 Asmacure Ltée Method of treating and preventing arthritis, cutaneous and cardiovascular inflammatory-related diseases using nicotinic receptor agonists
AU2005258274A1 (en) * 2004-06-23 2006-01-05 The Feinstein For Medical Research Method of treating ileus by pharmacological activation of cholinergic receptors
US7664551B2 (en) * 2004-07-07 2010-02-16 Medtronic Transneuronix, Inc. Treatment of the autonomic nervous system
US8821559B2 (en) * 2004-08-27 2014-09-02 Codman & Shurtleff, Inc. Light-based implants for treating Alzheimer's disease
JP5710092B2 (ja) * 2004-09-24 2015-04-30 ユニヴァーシティ オヴ メリーランド、バルティモア 有機リン中毒を治療する方法
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US7295874B2 (en) * 2005-01-06 2007-11-13 Cardiac Pacemakers, Inc. Intermittent stress augmentation pacing for cardioprotective effect
WO2006081332A1 (en) * 2005-01-25 2006-08-03 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
US8609082B2 (en) 2005-01-25 2013-12-17 Bio Control Medical Ltd. Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis
US8565867B2 (en) 2005-01-28 2013-10-22 Cyberonics, Inc. Changeable electrode polarity stimulation by an implantable medical device
US8260426B2 (en) 2008-01-25 2012-09-04 Cyberonics, Inc. Method, apparatus and system for bipolar charge utilization during stimulation by an implantable medical device
US9314633B2 (en) 2008-01-25 2016-04-19 Cyberonics, Inc. Contingent cardio-protection for epilepsy patients
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
US8700163B2 (en) 2005-03-04 2014-04-15 Cyberonics, Inc. Cranial nerve stimulation for treatment of substance addiction
USRE47266E1 (en) * 2005-03-14 2019-03-05 DePuy Synthes Products, Inc. Light-based implants for treating Alzheimer's disease
US7288108B2 (en) * 2005-03-14 2007-10-30 Codman & Shurtleff, Inc. Red light implant for treating Parkinson's disease
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7493161B2 (en) 2005-05-10 2009-02-17 Cardiac Pacemakers, Inc. System and method to deliver therapy in presence of another therapy
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
US7310557B2 (en) * 2005-04-29 2007-12-18 Maschino Steven E Identification of electrodes for nerve stimulation in the treatment of eating disorders
US7899540B2 (en) * 2005-04-29 2011-03-01 Cyberonics, Inc. Noninvasively adjustable gastric band
US7835796B2 (en) * 2005-04-29 2010-11-16 Cyberonics, Inc. Weight loss method and device
EP1893576A4 (en) * 2005-05-27 2010-03-17 Univ Kingston TREATMENT OF PROTEIN DISORDERING
US7922669B2 (en) 2005-06-08 2011-04-12 Cardiac Pacemakers, Inc. Ischemia detection using a heart sound sensor
US7351253B2 (en) * 2005-06-16 2008-04-01 Codman & Shurtleff, Inc. Intranasal red light probe for treating Alzheimer's disease
US7840280B2 (en) * 2005-07-27 2010-11-23 Cyberonics, Inc. Cranial nerve stimulation to treat a vocal cord disorder
US7706874B2 (en) 2005-07-28 2010-04-27 Cyberonics, Inc. Stimulating cranial nerve to treat disorders associated with the thyroid gland
US8660647B2 (en) * 2005-07-28 2014-02-25 Cyberonics, Inc. Stimulating cranial nerve to treat pulmonary disorder
US7856273B2 (en) 2005-07-28 2010-12-21 Cyberonics, Inc. Autonomic nerve stimulation to treat a gastrointestinal disorder
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7822486B2 (en) 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
US20070073354A1 (en) 2005-09-26 2007-03-29 Knudson Mark B Neural blocking therapy
JP4872044B2 (ja) * 2005-09-30 2012-02-08 財団法人ヒューマンサイエンス振興財団 心臓リモデリング抑制薬および心不全治療薬
JP3876325B1 (ja) * 2005-10-24 2007-01-31 国立大学法人 岡山大学 脳梗塞抑制剤
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
US7620455B2 (en) 2005-10-25 2009-11-17 Cyberonics, Inc. Cranial nerve stimulation to treat eating disorders
US7819907B2 (en) * 2005-10-31 2010-10-26 Codman & Shurtleff, Inc. Device and method for fixing adjacent bone plates
US10537728B2 (en) 2005-11-10 2020-01-21 ElectroCore, LLC Vagal nerve stimulation to avert or treat stroke or transient ischemic attack
US8983628B2 (en) 2009-03-20 2015-03-17 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US20110125203A1 (en) 2009-03-20 2011-05-26 ElectroCore, LLC. Magnetic Stimulation Devices and Methods of Therapy
US9174066B2 (en) 2009-03-20 2015-11-03 ElectroCore, LLC Devices and methods for non-invasive capacitive electrical stimulation and their use for vagus nerve stimulation on the neck of a patient
US20090234417A1 (en) * 2005-11-10 2009-09-17 Electrocore, Inc. Methods And Apparatus For The Treatment Of Metabolic Disorders
US8874227B2 (en) 2009-03-20 2014-10-28 ElectroCore, LLC Devices and methods for non-invasive capacitive electrical stimulation and their use for vagus nerve stimulation on the neck of a patient
US10441780B2 (en) 2005-11-10 2019-10-15 Electrocore, Inc. Systems and methods for vagal nerve stimulation
US8676330B2 (en) 2009-03-20 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
US11297445B2 (en) 2005-11-10 2022-04-05 Electrocore, Inc. Methods and devices for treating primary headache
US20070106337A1 (en) * 2005-11-10 2007-05-10 Electrocore, Inc. Methods And Apparatus For Treating Disorders Through Neurological And/Or Muscular Intervention
US8676324B2 (en) 2005-11-10 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
US11351363B2 (en) 2005-11-10 2022-06-07 Electrocore, Inc. Nerve stimulation devices and methods for treating cardiac arrhythmias
US9126050B2 (en) 2009-03-20 2015-09-08 ElectroCore, LLC Non-invasive vagus nerve stimulation devices and methods to treat or avert atrial fibrillation
US8868177B2 (en) * 2009-03-20 2014-10-21 ElectroCore, LLC Non-invasive treatment of neurodegenerative diseases
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2633655A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
US7570999B2 (en) 2005-12-20 2009-08-04 Cardiac Pacemakers, Inc. Implantable device for treating epilepsy and cardiac rhythm disorders
US20070150027A1 (en) * 2005-12-22 2007-06-28 Rogers Lesco L Non-invasive device and method for electrical stimulation of neural tissue
US7885710B2 (en) 2005-12-23 2011-02-08 Cardiac Pacemakers, Inc. Method and apparatus for tissue protection against ischemia using remote conditioning
US7610100B2 (en) * 2005-12-30 2009-10-27 Boston Scientific Neuromodulation Corporation Methods and systems for treating osteoarthritis
US7813805B1 (en) * 2006-01-11 2010-10-12 Pacesetter, Inc. Subcardiac threshold vagal nerve stimulation
US7996079B2 (en) 2006-01-24 2011-08-09 Cyberonics, Inc. Input response override for an implantable medical device
US7657310B2 (en) 2006-01-26 2010-02-02 Cyberonics, Inc. Treatment of reproductive endocrine disorders by vagus nerve stimulation
US7974697B2 (en) * 2006-01-26 2011-07-05 Cyberonics, Inc. Medical imaging feedback for an implantable medical device
US20070191904A1 (en) * 2006-02-14 2007-08-16 Imad Libbus Expandable stimulation electrode with integrated pressure sensor and methods related thereto
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
EP2026874B1 (en) 2006-03-29 2015-05-20 Dignity Health Vagus nerve stimulation system
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US20100174340A1 (en) * 2006-04-18 2010-07-08 Electrocore, Inc. Methods and Apparatus for Applying Energy to Patients
US20100057178A1 (en) * 2006-04-18 2010-03-04 Electrocore, Inc. Methods and apparatus for spinal cord stimulation using expandable electrode
US8209034B2 (en) * 2008-12-18 2012-06-26 Electrocore Llc Methods and apparatus for electrical stimulation treatment using esophageal balloon and electrode
US8401650B2 (en) * 2008-04-10 2013-03-19 Electrocore Llc Methods and apparatus for electrical treatment using balloon and electrode
US20100241188A1 (en) * 2009-03-20 2010-09-23 Electrocore, Inc. Percutaneous Electrical Treatment Of Tissue
US20090157138A1 (en) * 2006-04-18 2009-06-18 Electrocore, Inc. Methods And Apparatus For Treating Ileus Condition Using Electrical Signals
US8652201B2 (en) 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
US7962220B2 (en) 2006-04-28 2011-06-14 Cyberonics, Inc. Compensation reduction in tissue stimulation therapy
US7869885B2 (en) 2006-04-28 2011-01-11 Cyberonics, Inc Threshold optimization for tissue stimulation therapy
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US8170668B2 (en) 2006-07-14 2012-05-01 Cardiac Pacemakers, Inc. Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
US7869867B2 (en) 2006-10-27 2011-01-11 Cyberonics, Inc. Implantable neurostimulator with refractory stimulation
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008089360A1 (en) * 2007-01-17 2008-07-24 The Cleveland Clinic Foundation Apparatus and methods for treating pulmonary conditions
US7706875B2 (en) * 2007-01-25 2010-04-27 Cyberonics, Inc. Modulation of drug effects by vagus nerve stimulation
ES2430613T3 (es) 2007-01-29 2013-11-21 Simon Fraser University Aparato de neuroestimulación transvascular
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
US8615296B2 (en) 2007-03-06 2013-12-24 Cardiac Pacemakers, Inc. Method and apparatus for closed-loop intermittent cardiac stress augmentation pacing
WO2008112915A1 (en) * 2007-03-13 2008-09-18 The Feinstein Institute For Medical Research Treatment of inflammation by non-invasive stimulation
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US7904175B2 (en) 2007-04-26 2011-03-08 Cyberonics, Inc. Trans-esophageal vagus nerve stimulation
US7962214B2 (en) 2007-04-26 2011-06-14 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7869884B2 (en) 2007-04-26 2011-01-11 Cyberonics, Inc. Non-surgical device and methods for trans-esophageal vagus nerve stimulation
US7974701B2 (en) 2007-04-27 2011-07-05 Cyberonics, Inc. Dosing limitation for an implantable medical device
US8983609B2 (en) * 2007-05-30 2015-03-17 The Cleveland Clinic Foundation Apparatus and method for treating pulmonary conditions
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
US8160695B2 (en) * 2007-12-05 2012-04-17 The Invention Science Fund I, Llc System for chemical modulation of neural activity
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US8155744B2 (en) 2007-12-13 2012-04-10 The Cleveland Clinic Foundation Neuromodulatory methods for treating pulmonary disorders
US8571643B2 (en) 2010-09-16 2013-10-29 Flint Hills Scientific, Llc Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex
US8382667B2 (en) 2010-10-01 2013-02-26 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
US8337404B2 (en) 2010-10-01 2012-12-25 Flint Hills Scientific, Llc Detecting, quantifying, and/or classifying seizures using multimodal data
WO2009097118A1 (en) 2008-01-29 2009-08-06 Cardiac Pacemakers, Inc Configurable intermittent pacing therapy
US9320914B2 (en) 2008-03-03 2016-04-26 DePuy Synthes Products, Inc. Endoscopic delivery of red/NIR light to the subventricular zone
US8140155B2 (en) * 2008-03-11 2012-03-20 Cardiac Pacemakers, Inc. Intermittent pacing therapy delivery statistics
WO2009117086A2 (en) 2008-03-17 2009-09-24 Cardiac Pacemakers, Inc. Deactivation of intermittent pacing therapy
US20090239901A1 (en) * 2008-03-19 2009-09-24 Merouane Bencherif Method and compositions for treatment of cerebral malaria
US8682449B2 (en) 2008-04-10 2014-03-25 ElectroCore, LLC Methods and apparatus for transcranial stimulation
US8543211B2 (en) 2008-04-10 2013-09-24 ElectroCore, LLC Methods and apparatus for deep brain stimulation
US8204603B2 (en) 2008-04-25 2012-06-19 Cyberonics, Inc. Blocking exogenous action potentials by an implantable medical device
US20090275997A1 (en) * 2008-05-01 2009-11-05 Michael Allen Faltys Vagus nerve stimulation electrodes and methods of use
US8473062B2 (en) 2008-05-01 2013-06-25 Autonomic Technologies, Inc. Method and device for the treatment of headache
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8457747B2 (en) 2008-10-20 2013-06-04 Cyberonics, Inc. Neurostimulation with signal duration determined by a cardiac cycle
US8417344B2 (en) 2008-10-24 2013-04-09 Cyberonics, Inc. Dynamic cranial nerve stimulation based on brain state determination from cardiac data
US8255057B2 (en) 2009-01-29 2012-08-28 Nevro Corporation Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions
US8412336B2 (en) 2008-12-29 2013-04-02 Autonomic Technologies, Inc. Integrated delivery and visualization tool for a neuromodulation system
US9320908B2 (en) 2009-01-15 2016-04-26 Autonomic Technologies, Inc. Approval per use implanted neurostimulator
US8494641B2 (en) 2009-04-22 2013-07-23 Autonomic Technologies, Inc. Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism
US20100191304A1 (en) 2009-01-23 2010-07-29 Scott Timothy L Implantable Medical Device for Providing Chronic Condition Therapy and Acute Condition Therapy Using Vagus Nerve Stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US20100198316A1 (en) * 2009-02-04 2010-08-05 Richard Toselli Intracranial Red Light Treatment Device For Chronic Pain
US11229790B2 (en) 2013-01-15 2022-01-25 Electrocore, Inc. Mobile phone for treating a patient with seizures
US10286212B2 (en) 2009-03-20 2019-05-14 Electrocore, Inc. Nerve stimulation methods for averting imminent onset or episode of a disease
US10220207B2 (en) 2009-03-20 2019-03-05 Electrocore, Inc. Nerve stimulation methods for averting imminent onset or episode of a disease
US9403001B2 (en) 2009-03-20 2016-08-02 ElectroCore, LLC Non-invasive magnetic or electrical nerve stimulation to treat gastroparesis, functional dyspepsia, and other functional gastrointestinal disorders
US8918178B2 (en) 2009-03-20 2014-12-23 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US20190240486A1 (en) 2009-03-20 2019-08-08 Electrocore, Inc. Non-invasive treatment of neurodegenerative diseases
US10376696B2 (en) 2009-03-20 2019-08-13 Electrocore, Inc. Medical self-treatment using non-invasive vagus nerve stimulation
US10252074B2 (en) 2009-03-20 2019-04-09 ElectroCore, LLC Nerve stimulation methods for averting imminent onset or episode of a disease
US10232178B2 (en) 2009-03-20 2019-03-19 Electrocore, Inc. Non-invasive magnetic or electrical nerve stimulation to treat or prevent dementia
US9254383B2 (en) 2009-03-20 2016-02-09 ElectroCore, LLC Devices and methods for monitoring non-invasive vagus nerve stimulation
US9248286B2 (en) 2009-03-20 2016-02-02 ElectroCore, LLC Medical self-treatment using non-invasive vagus nerve stimulation
US10512769B2 (en) 2009-03-20 2019-12-24 Electrocore, Inc. Non-invasive magnetic or electrical nerve stimulation to treat or prevent autism spectrum disorders and other disorders of psychological development
US9375571B2 (en) 2013-01-15 2016-06-28 ElectroCore, LLC Mobile phone using non-invasive nerve stimulation
US8983629B2 (en) 2009-03-20 2015-03-17 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US9333347B2 (en) 2010-08-19 2016-05-10 ElectroCore, LLC Devices and methods for non-invasive electrical stimulation and their use for vagal nerve stimulation on the neck of a patient
US9174045B2 (en) 2009-03-20 2015-11-03 ElectroCore, LLC Non-invasive electrical and magnetic nerve stimulators used to treat overactive bladder and urinary incontinence
US8827912B2 (en) 2009-04-24 2014-09-09 Cyberonics, Inc. Methods and systems for detecting epileptic events using NNXX, optionally with nonlinear analysis parameters
US8239028B2 (en) 2009-04-24 2012-08-07 Cyberonics, Inc. Use of cardiac parameters in methods and systems for treating a chronic medical condition
US8483832B2 (en) 2009-05-20 2013-07-09 ElectroCore, LLC Systems and methods for selectively applying electrical energy to tissue
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8958873B2 (en) 2009-05-28 2015-02-17 Cardiac Pacemakers, Inc. Method and apparatus for safe and efficient delivery of cardiac stress augmentation pacing
US8812104B2 (en) 2009-09-23 2014-08-19 Cardiac Pacemakers, Inc. Method and apparatus for automated control of pacing post-conditioning
EP2493560A1 (en) 2009-10-30 2012-09-05 Cardiac Pacemakers, Inc. Pacemaker with vagal surge monitoring and response
US8321012B2 (en) 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
US20110224606A1 (en) * 2010-03-10 2011-09-15 Shibaji Shome Method and apparatus for remote ischemic conditioning during revascularization
US8831732B2 (en) 2010-04-29 2014-09-09 Cyberonics, Inc. Method, apparatus and system for validating and quantifying cardiac beat data quality
US8649871B2 (en) 2010-04-29 2014-02-11 Cyberonics, Inc. Validity test adaptive constraint modification for cardiac data used for detection of state changes
US8562536B2 (en) 2010-04-29 2013-10-22 Flint Hills Scientific, Llc Algorithm for detecting a seizure from cardiac data
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US8788045B2 (en) 2010-06-08 2014-07-22 Bluewind Medical Ltd. Tibial nerve stimulation
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US8679009B2 (en) 2010-06-15 2014-03-25 Flint Hills Scientific, Llc Systems approach to comorbidity assessment
US8641646B2 (en) 2010-07-30 2014-02-04 Cyberonics, Inc. Seizure detection using coordinate data
US11191953B2 (en) 2010-08-19 2021-12-07 Electrocore, Inc. Systems and methods for vagal nerve stimulation
US11400288B2 (en) 2010-08-19 2022-08-02 Electrocore, Inc Devices and methods for electrical stimulation and their use for vagus nerve stimulation on the neck of a patient
US9358381B2 (en) 2011-03-10 2016-06-07 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US12208263B2 (en) 2011-01-12 2025-01-28 Electrocore, Inc. Devices and methods for non-invasive vagal nerve stimulation
US20200086108A1 (en) 2010-08-19 2020-03-19 Electrocore, Inc. Vagal nerve stimulation to reduce inflammation associated with an aneurysm
US12377260B2 (en) 2010-08-19 2025-08-05 Electrocord, Inc. Vagal nerve stimulation
US8562524B2 (en) 2011-03-04 2013-10-22 Flint Hills Scientific, Llc Detecting, assessing and managing a risk of death in epilepsy
US8684921B2 (en) 2010-10-01 2014-04-01 Flint Hills Scientific Llc Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis
US12383190B2 (en) 2011-03-04 2025-08-12 Flint Hills Scientific, Llc Detecting, assessing and managing extreme seizure events
US8562523B2 (en) 2011-03-04 2013-10-22 Flint Hills Scientific, Llc Detecting, assessing and managing extreme epileptic events
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US9457186B2 (en) 2010-11-15 2016-10-04 Bluewind Medical Ltd. Bilateral feedback
US9186504B2 (en) 2010-11-15 2015-11-17 Rainbow Medical Ltd Sleep apnea treatment
US12168121B2 (en) 2010-11-19 2024-12-17 Electrocore, Inc. Devices and methods for treating or preventing development disorders
US11432760B2 (en) 2011-01-12 2022-09-06 Electrocore, Inc. Devices and methods for remote therapy and patient monitoring
US9504390B2 (en) 2011-03-04 2016-11-29 Globalfoundries Inc. Detecting, assessing and managing a risk of death in epilepsy
US11511109B2 (en) 2011-03-10 2022-11-29 Electrocore, Inc. Non-invasive magnetic or electrical nerve stimulation to treat gastroparesis, functional dyspepsia, and other functional gastrointestinal disorders
US12594418B2 (en) 2011-03-10 2026-04-07 Electrocore, Inc. Devices and methods for nerve stimulation
US10279163B2 (en) 2011-03-10 2019-05-07 Electrocore, Inc. Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
US11458297B2 (en) 2011-03-10 2022-10-04 Electrocore, Inc Electrical and magnetic stimulators used to treat migraine/sinus headache, rhinitis, sinusitis, rhinosinusitis, and comorbid disorders
US9399134B2 (en) 2011-03-10 2016-07-26 ElectroCore, LLC Non-invasive vagal nerve stimulation to treat disorders
US8725239B2 (en) 2011-04-25 2014-05-13 Cyberonics, Inc. Identifying seizures using heart rate decrease
US9402550B2 (en) 2011-04-29 2016-08-02 Cybertronics, Inc. Dynamic heart rate threshold for neurological event detection
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US9566426B2 (en) 2011-08-31 2017-02-14 ElectroCore, LLC Systems and methods for vagal nerve stimulation
US9549677B2 (en) 2011-10-14 2017-01-24 Flint Hills Scientific, L.L.C. Seizure detection methods, apparatus, and systems using a wavelet transform maximum modulus algorithm
US8918191B2 (en) 2011-12-07 2014-12-23 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration
US10188856B1 (en) 2011-12-07 2019-01-29 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US8577458B1 (en) 2011-12-07 2013-11-05 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with leadless heart rate monitoring
US8918190B2 (en) 2011-12-07 2014-12-23 Cyberonics, Inc. Implantable device for evaluating autonomic cardiovascular drive in a patient suffering from chronic cardiac dysfunction
US8600505B2 (en) 2011-12-07 2013-12-03 Cyberonics, Inc. Implantable device for facilitating control of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US8630709B2 (en) 2011-12-07 2014-01-14 Cyberonics, Inc. Computer-implemented system and method for selecting therapy profiles of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US8700150B2 (en) 2012-01-17 2014-04-15 Cyberonics, Inc. Implantable neurostimulator for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration
US8571654B2 (en) 2012-01-17 2013-10-29 Cyberonics, Inc. Vagus nerve neurostimulator with multiple patient-selectable modes for treating chronic cardiac dysfunction
US20150018728A1 (en) 2012-01-26 2015-01-15 Bluewind Medical Ltd. Wireless neurostimulators
CN104271195B (zh) 2012-03-05 2017-04-19 西蒙·弗雷瑟大学 经血管神经刺激设备及方法
US10448839B2 (en) 2012-04-23 2019-10-22 Livanova Usa, Inc. Methods, systems and apparatuses for detecting increased risk of sudden death
WO2013188965A1 (en) 2012-06-21 2013-12-27 Simon Fraser University Transvascular diaphragm pacing systems and methods of use
US8688212B2 (en) 2012-07-20 2014-04-01 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing bradycardia through vagus nerve stimulation
US8504161B1 (en) 2012-08-07 2013-08-06 Medtronic, Inc. Modulate vagal signals to reduce inflammation
US9770593B2 (en) 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
WO2014068577A2 (en) 2012-11-05 2014-05-08 Rainbow Medical Ltd. Controlled tissue ablation
US9452290B2 (en) 2012-11-09 2016-09-27 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing tachyarrhythmia through vagus nerve stimulation
US8923964B2 (en) 2012-11-09 2014-12-30 Cyberonics, Inc. Implantable neurostimulator-implemented method for enhancing heart failure patient awakening through vagus nerve stimulation
US9643008B2 (en) 2012-11-09 2017-05-09 Cyberonics, Inc. Implantable neurostimulator-implemented method for enhancing post-exercise recovery through vagus nerve stimulation
US9861812B2 (en) 2012-12-06 2018-01-09 Blue Wind Medical Ltd. Delivery of implantable neurostimulators
US10293160B2 (en) 2013-01-15 2019-05-21 Electrocore, Inc. Mobile phone for treating a patient with dementia
US9435830B2 (en) 2013-01-18 2016-09-06 Cyberonics, Inc. Implantable medical device depth estimation
US10220211B2 (en) 2013-01-22 2019-03-05 Livanova Usa, Inc. Methods and systems to diagnose depression
US9174049B2 (en) 2013-01-27 2015-11-03 ElectroCore, LLC Systems and methods for electrical stimulation of sphenopalatine ganglion and other branches of cranial nerves
US9643011B2 (en) 2013-03-14 2017-05-09 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing tachyarrhythmic risk during sleep through vagus nerve stimulation
US9056195B2 (en) 2013-03-15 2015-06-16 Cyberonics, Inc. Optimization of cranial nerve stimulation to treat seizure disorderse during sleep
US9370660B2 (en) 2013-03-29 2016-06-21 Rainbow Medical Ltd. Independently-controlled bidirectional nerve stimulation
US9427581B2 (en) 2013-04-28 2016-08-30 ElectroCore, LLC Devices and methods for treating medical disorders with evoked potentials and vagus nerve stimulation
EP3049438B1 (en) 2013-09-24 2018-07-25 The Feinstein Institute for Medical Research Peptides inhibiting cold-inducible rna binding protein activity
US9999773B2 (en) 2013-10-30 2018-06-19 Cyberonics, Inc. Implantable neurostimulator-implemented method utilizing multi-modal stimulation parameters
US9205258B2 (en) 2013-11-04 2015-12-08 ElectroCore, LLC Nerve stimulator system
CN105873630B (zh) 2013-11-22 2020-01-03 隆佩瑟尔医疗公司 用于通过经血管神经刺激辅助呼吸的装置和方法
US9511228B2 (en) 2014-01-14 2016-12-06 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing hypertension through renal denervation and vagus nerve stimulation
EP3096835B1 (en) 2014-01-21 2019-08-07 Lungpacer Medical Inc. Systems for optimization of multi-electrode nerve pacing
US9409024B2 (en) 2014-03-25 2016-08-09 Cyberonics, Inc. Neurostimulation in a neural fulcrum zone for the treatment of chronic cardiac dysfunction
US9272143B2 (en) 2014-05-07 2016-03-01 Cyberonics, Inc. Responsive neurostimulation for the treatment of chronic cardiac dysfunction
US9415224B2 (en) 2014-04-25 2016-08-16 Cyberonics, Inc. Neurostimulation and recording of physiological response for the treatment of chronic cardiac dysfunction
US9950169B2 (en) 2014-04-25 2018-04-24 Cyberonics, Inc. Dynamic stimulation adjustment for identification of a neural fulcrum
US9713719B2 (en) 2014-04-17 2017-07-25 Cyberonics, Inc. Fine resolution identification of a neural fulcrum for the treatment of chronic cardiac dysfunction
US9585611B2 (en) 2014-04-25 2017-03-07 Cyberonics, Inc. Detecting seizures based on heartbeat data
US9302109B2 (en) 2014-04-25 2016-04-05 Cyberonics, Inc. Cranial nerve stimulation to treat depression during sleep
WO2015170281A1 (en) 2014-05-07 2015-11-12 Rainbow Medical Ltd Controlled tissue ablation techniques
US9782584B2 (en) 2014-06-13 2017-10-10 Nervana, LLC Transcutaneous electrostimulator and methods for electric stimulation
US10130809B2 (en) 2014-06-13 2018-11-20 Nervana, LLC Transcutaneous electrostimulator and methods for electric stimulation
US9737716B2 (en) 2014-08-12 2017-08-22 Cyberonics, Inc. Vagus nerve and carotid baroreceptor stimulation system
US9533153B2 (en) 2014-08-12 2017-01-03 Cyberonics, Inc. Neurostimulation titration process
US9770599B2 (en) 2014-08-12 2017-09-26 Cyberonics, Inc. Vagus nerve stimulation and subcutaneous defibrillation system
US9504832B2 (en) 2014-11-12 2016-11-29 Cyberonics, Inc. Neurostimulation titration process via adaptive parametric modification
US10004896B2 (en) 2015-01-21 2018-06-26 Bluewind Medical Ltd. Anchors and implant devices
US9597521B2 (en) 2015-01-21 2017-03-21 Bluewind Medical Ltd. Transmitting coils for neurostimulation
US9764146B2 (en) 2015-01-21 2017-09-19 Bluewind Medical Ltd. Extracorporeal implant controllers
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
US9782589B2 (en) 2015-06-10 2017-10-10 Bluewind Medical Ltd. Implantable electrostimulator for improving blood flow
US11318310B1 (en) 2015-10-26 2022-05-03 Nevro Corp. Neuromodulation for altering autonomic functions, and associated systems and methods
US10105540B2 (en) 2015-11-09 2018-10-23 Bluewind Medical Ltd. Optimization of application of current
US9713707B2 (en) 2015-11-12 2017-07-25 Bluewind Medical Ltd. Inhibition of implant migration
US11678932B2 (en) 2016-05-18 2023-06-20 Symap Medical (Suzhou) Limited Electrode catheter with incremental advancement
US10335396B2 (en) 2016-10-27 2019-07-02 Patrick M. Nemechek Methods of reversing autonomic nervous system damage
US10124178B2 (en) 2016-11-23 2018-11-13 Bluewind Medical Ltd. Implant and delivery tool therefor
US10293164B2 (en) 2017-05-26 2019-05-21 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US20180353764A1 (en) 2017-06-13 2018-12-13 Bluewind Medical Ltd. Antenna configuration
JP7184370B2 (ja) 2017-06-30 2022-12-06 ラングペーサー メディカル インコーポレイテッド 認知障害の予防、緩和、及び／または治療のための装置
US10195429B1 (en) 2017-08-02 2019-02-05 Lungpacer Medical Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10940308B2 (en) 2017-08-04 2021-03-09 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment
EP3470111B1 (en) 2017-10-13 2025-12-31 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US20190175908A1 (en) 2017-12-11 2019-06-13 Lungpacer Medical Inc. Systems and methods for strengthening a respiratory muscle
KR20210008328A (ko) 2018-03-07 2021-01-21 수부 랩스, 인크. 열 섬유의 자극을 통한 통증 완화 개선을 위한 시스템 및 방법
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
WO2020068830A1 (en) 2018-09-24 2020-04-02 Vivek Sharma Auricular nerve stimulation to address patient disorders, and associated systems and methods
WO2020097331A1 (en) 2018-11-08 2020-05-14 Lungpacer Medical Inc. Stimulation systems and related user interfaces
US20230414928A1 (en) 2022-05-20 2023-12-28 Spark Biomedical, Inc. Devices and methods for treating stress and improving alertness using electrical stimulation
US11590352B2 (en) 2019-01-29 2023-02-28 Nevro Corp. Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods
US11357979B2 (en) 2019-05-16 2022-06-14 Lungpacer Medical Inc. Systems and methods for sensing and stimulation
WO2020252037A1 (en) 2019-06-12 2020-12-17 Lungpacer Medical Inc. Circuitry for medical stimulation systems
US11123560B1 (en) 2020-06-08 2021-09-21 Patrick M. Nemechek Methods of treating covid-19 induced cytokine storm
CN112023050A (zh) * 2020-09-10 2020-12-04 中国科学院深圳先进技术研究院 一种调节巨噬细胞极化状态的方法
EP4347001B1 (en) 2021-05-25 2026-03-25 Nevro Corp. Modified high frequency neuromodulation signals, and associated systems
US11400299B1 (en) 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator
CN116773804B (zh) * 2022-10-19 2026-02-10 陕西脉元生物科技有限公司 一种检测AChR阻断型抗体的试剂盒、检测方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567724A (en) * 1993-06-01 1996-10-22 Cortex Pharmaceuticals, Inc. Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5709853A (en) * 1994-01-28 1998-01-20 Toray Industries, Inc. Method of treatment of atopic disease
US5733255A (en) * 1995-10-18 1998-03-31 Novartis Finance Corporation Thermopile powered transdermal drug delivery device
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166048A (en) 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
US6116048A (en) * 1997-02-18 2000-09-12 Hebert; Thomas H. Dual evaporator for indoor units and method therefor
US5994330A (en) * 1998-11-09 1999-11-30 El Khoury; Georges F. Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567724A (en) * 1993-06-01 1996-10-22 Cortex Pharmaceuticals, Inc. Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
US5709853A (en) * 1994-01-28 1998-01-20 Toray Industries, Inc. Method of treatment of atopic disease
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5733255A (en) * 1995-10-18 1998-03-31 Novartis Finance Corporation Thermopile powered transdermal drug delivery device
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1307196A1 *

Cited By (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8036741B2 (en) 1996-04-30 2011-10-11 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US7184829B2 (en) 1996-04-30 2007-02-27 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
US7269457B2 (en) 1996-04-30 2007-09-11 Medtronic, Inc. Method and system for vagal nerve stimulation with multi-site cardiac pacing
US7310552B2 (en) 1997-08-26 2007-12-18 Puskas John D Apparatus for indirectly stimulating the vagus nerve with an electrical field
US10561846B2 (en) 2000-05-23 2020-02-18 The Feinstein Institutes For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US9987492B2 (en) 2000-05-23 2018-06-05 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US10166395B2 (en) 2000-05-23 2019-01-01 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US7184828B2 (en) 2000-09-26 2007-02-27 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
WO2003072135A3 (en) * 2002-02-26 2004-07-22 Long Island Jewish Res Inst Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
WO2004004763A3 (en) * 2002-07-03 2004-02-26 San Raffaele Centro Fond Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
US20110245286A1 (en) * 2002-12-06 2011-10-06 The Feinstein Institute For Medical Research Treatment of inflammation using alpha 7 receptor-binding agonists
EP1581223B2 (en) † 2002-12-06 2016-05-25 The Feinstein Institute for Medical Research Inhibition of inflamation using alpha 7 receptor-binding cholinergic agonists
EP1949901A3 (en) * 2002-12-06 2008-10-15 The Feinstein Institute for Medical Research Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists
US7785808B2 (en) 2002-12-06 2010-08-31 The Feinstein Institute For Medical Research Treatment of inflammation using α7 receptor-binding cholinergic agonists
CN102657651A (zh) * 2002-12-06 2012-09-12 范因斯坦医学研究院 用α 7受体结合胆碱能激动剂抑制炎症
JP2011105745A (ja) * 2002-12-06 2011-06-02 North Shore-Long Island Jewish Research Inst α７受容体結合コリン作動性アゴニストを用いる炎症の阻害
US10953170B2 (en) 2003-05-13 2021-03-23 Nuvaira, Inc. Apparatus for treating asthma using neurotoxin
US9339618B2 (en) 2003-05-13 2016-05-17 Holaira, Inc. Method and apparatus for controlling narrowing of at least one airway
US7668602B2 (en) 2003-06-13 2010-02-23 Bio Control Medical (B.C.M.) Ltd. Minimal-heart-rate reduction parasympathetic stimulation
US7418292B2 (en) 2003-10-01 2008-08-26 Medtronic, Inc. Device and method for attenuating an immune response
US8003632B2 (en) 2004-01-27 2011-08-23 The Feinstein Institute For Medical Research Cholinesterase inhibitors for treating inflammation
WO2005072713A3 (en) * 2004-01-27 2005-12-08 Long Island Jewish Res Inst Cholinesterase inhibitors for treating inflammation
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US11344724B2 (en) 2004-12-27 2022-05-31 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
AU2006315829B2 (en) * 2005-11-10 2011-01-27 ElectroCore, LLC. Electrical stimulation treatment of bronchial constriction
US9037247B2 (en) 2005-11-10 2015-05-19 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US7747324B2 (en) 2005-11-10 2010-06-29 Electrocore Llc Electrical stimulation treatment of bronchial constriction
EP1948301A4 (en) * 2005-11-10 2009-10-14 Electrocore Inc TREATMENT OF BRONCHIC CONSTRICTION BY ELECTRICAL STIMULATION
US8812112B2 (en) 2005-11-10 2014-08-19 ElectroCore, LLC Electrical treatment of bronchial constriction
US8840537B2 (en) 2005-11-10 2014-09-23 ElectroCore, LLC Non-invasive treatment of bronchial constriction
US8524866B2 (en) 2005-11-15 2013-09-03 The Feinstein Institute For Medical Research Antibodies to the alpha-7 nicotinic receptors and methods of treating inflammatory disorders with the same
US8612004B2 (en) 2006-02-10 2013-12-17 ElectroCore, LLC Electrical stimulation treatment of hypotension
US8099167B1 (en) 2006-02-10 2012-01-17 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US8483835B2 (en) 2006-02-10 2013-07-09 ElectroCore, LLC Methods and apparatus for treating anaphylaxis using electrical modulation
US8010197B2 (en) 2006-02-10 2011-08-30 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
US8041428B2 (en) 2006-02-10 2011-10-18 Electrocore Llc Electrical stimulation treatment of hypotension
US7711430B2 (en) 2006-02-10 2010-05-04 Electrocore Llc Methods and apparatus for treating anaphylaxis using electrical modulation
AU2006338184B2 (en) * 2006-02-10 2011-11-24 ElectroCore, LLC. Electrical stimulation treatment of hypotension
US7725188B2 (en) 2006-02-10 2010-05-25 Electrocore Llc Electrical stimulation treatment of hypotension
US8204598B2 (en) 2006-02-10 2012-06-19 Electrocore Llc Methods and apparatus for treating bronchial restriction using electrical modulation
US7869879B2 (en) 2006-02-10 2011-01-11 Electrocore Llc Electrical stimulation treatment of hypotension
US8233988B2 (en) 2006-02-10 2012-07-31 Electrocore Llc Electrical stimulation treatment of hypotension
EP2801359A3 (en) * 2006-05-08 2015-05-06 Arturo Solis Herrera The use of nicotine for the treatment of sepsis in humans caused by antibiotic
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US12357827B2 (en) 2008-02-15 2025-07-15 Nuvaira, Inc. System and method for bronchial dilation
US11058879B2 (en) 2008-02-15 2021-07-13 Nuvaira, Inc. System and method for bronchial dilation
US9125643B2 (en) 2008-02-15 2015-09-08 Holaira, Inc. System and method for bronchial dilation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US10149714B2 (en) 2008-05-09 2018-12-11 Nuvaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US11937868B2 (en) 2008-05-09 2024-03-26 Nuvaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US9668809B2 (en) 2008-05-09 2017-06-06 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8961507B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8961508B2 (en) 2008-05-09 2015-02-24 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
US9079031B2 (en) 2008-09-11 2015-07-14 Trifectas Medical Corp. Method for improving functional recovery after stroke by electrical stimulation of a cranial nerve
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US9849286B2 (en) 2009-05-01 2017-12-26 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US10716936B2 (en) 2009-06-09 2020-07-21 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9174041B2 (en) 2009-06-09 2015-11-03 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9700716B2 (en) 2009-06-09 2017-07-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US10220203B2 (en) 2009-06-09 2019-03-05 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US12251558B2 (en) 2009-06-09 2025-03-18 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8731663B2 (en) 2009-07-01 2014-05-20 Medtronic, Inc. Vagal stimulation during atrial tachyarrhythmia to facilitate cardiac resynchronization therapy
US9017324B2 (en) 2009-10-27 2015-04-28 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8932289B2 (en) 2009-10-27 2015-01-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9675412B2 (en) 2009-10-27 2017-06-13 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9005195B2 (en) 2009-10-27 2015-04-14 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US9649153B2 (en) 2009-10-27 2017-05-16 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US11712283B2 (en) 2009-11-11 2023-08-01 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US11389233B2 (en) 2009-11-11 2022-07-19 Nuvaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US12343060B2 (en) 2009-11-11 2025-07-01 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9649154B2 (en) 2009-11-11 2017-05-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US12290309B2 (en) 2009-11-11 2025-05-06 Nuvaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US10610283B2 (en) 2009-11-11 2020-04-07 Nuvaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US11110287B2 (en) 2009-12-23 2021-09-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8855767B2 (en) 2009-12-23 2014-10-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US12290695B2 (en) 2009-12-23 2025-05-06 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9993651B2 (en) 2009-12-23 2018-06-12 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8612002B2 (en) 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9162064B2 (en) 2009-12-23 2015-10-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US10384068B2 (en) 2009-12-23 2019-08-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8406868B2 (en) 2010-04-29 2013-03-26 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US10207112B2 (en) 2010-04-29 2019-02-19 Medtronic, Inc. Cardiac therapy including vagal stimulation
US9468764B2 (en) 2010-04-29 2016-10-18 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US11129988B2 (en) 2010-04-29 2021-09-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8423134B2 (en) 2010-04-29 2013-04-16 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8888699B2 (en) 2010-04-29 2014-11-18 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US9211413B2 (en) 2011-01-19 2015-12-15 Medtronic, Inc. Preventing use of vagal stimulation parameters
US9155893B2 (en) 2011-01-19 2015-10-13 Medtronic, Inc. Use of preventative vagal stimulation in treatment of acute myocardial infarction or ischemia
US12357826B2 (en) 2011-05-09 2025-07-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US9918996B2 (en) 2012-02-22 2018-03-20 Arturo Solis Herrera Methods of using qiapine
US9668969B1 (en) 2012-02-22 2017-06-06 Arturo Solis Herrera Methods of using QIAPINE
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US10449358B2 (en) 2012-03-26 2019-10-22 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US12402826B2 (en) 2013-04-10 2025-09-02 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US11969253B2 (en) 2013-04-10 2024-04-30 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US12383741B2 (en) 2014-10-24 2025-08-12 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US11446359B2 (en) 2015-04-27 2022-09-20 Tulavi Therapeutics, Inc. Systems and methods for cardiac plexus neuromodulation
US11278718B2 (en) 2016-01-13 2022-03-22 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US12121726B2 (en) 2016-01-20 2024-10-22 Setpoint Medical Corporation Control of vagal stimulation
US11547852B2 (en) 2016-01-20 2023-01-10 Setpoint Medical Corporation Control of vagal stimulation
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US12296169B2 (en) 2016-01-20 2025-05-13 Setpoint Medical Corporation Batteryless implantable microstimulators
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11964150B2 (en) 2016-01-20 2024-04-23 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US12472368B2 (en) 2016-01-25 2025-11-18 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11383091B2 (en) 2016-01-25 2022-07-12 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11918595B2 (en) 2016-02-09 2024-03-05 Tulavi Therapeutics, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
US11246879B2 (en) 2016-02-09 2022-02-15 Tulai Therapeutics, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
US11154547B2 (en) 2016-06-29 2021-10-26 Tulavi Therapeutics, Inc. Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
AU2017290353B2 (en) * 2016-06-29 2023-05-18 Tulavi Therapeutics, Inc. Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
US12029733B2 (en) 2016-06-29 2024-07-09 Tulavi Therapeutics, Inc. Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
EP3478287A4 (en) * 2016-06-29 2020-04-08 Tulavi Therapeutics, Inc. TREATMENT OF SEPTICEMIA AND ASSOCIATED INFLAMMATORY CONDITIONS BY LOCAL NEUROMODULATION OF THE AUTONOMOUS NERVOUS SYSTEM
CN110035754A (zh) * 2016-06-29 2019-07-19 图拉维治疗股份有限公司 通过自主神经系统的局部神经调节治疗败血症及相关炎性病况
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11890471B2 (en) 2017-08-14 2024-02-06 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
EP3768261A1 (en) * 2018-03-22 2021-01-27 NSC THERAPEUTICS GmbH Compounds and methods for use in the treatment of microglia-mediated disorders
US11944717B2 (en) 2018-07-02 2024-04-02 Tulavi Therapeutics, Inc. Devices for in situ formed nerve caps and/or nerve wraps
US12096941B2 (en) 2018-07-02 2024-09-24 Tulavi Therapeutics, Inc. Methods for forming a nerve barrier
US11890393B2 (en) 2018-07-02 2024-02-06 Tulavi Therapeutics, Inc. Methods and devices for in situ formed nerve cap
US12220579B2 (en) 2018-09-25 2025-02-11 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11857788B2 (en) 2018-09-25 2024-01-02 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US12533531B2 (en) 2020-01-13 2026-01-27 The Feinstein Institutes For Medical Research Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
US12465768B2 (en) 2020-05-21 2025-11-11 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US12582819B2 (en) 2022-01-20 2026-03-24 Setpoint Medical Corporation Treatment of inflammatory disorders

Also Published As

Publication number Publication date
US20020016344A1 (en) 2002-02-07
US6610713B2 (en) 2003-08-26
US20040038857A1 (en) 2004-02-26
AU2001261629B2 (en) 2005-05-26
EP1307196A1 (en) 2003-05-07
CA2408791A1 (en) 2001-11-29
AU6162901A (en) 2001-12-03
US6838471B2 (en) 2005-01-04
CA2408791C (en) 2014-09-16
EP1307196A4 (en) 2005-11-09
JP2004510695A (ja) 2004-04-08

Similar Documents

Publication Publication Date Title
US10561846B2 (en) Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6610713B2 (en) Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
AU2001261629A1 (en) Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20040048795A1 (en) Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
JP2021042248A (ja) Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
CN110121557A (zh) 可调节细胞系及其使用方法
JP2003535818A (ja) 哺乳動物細胞増殖を媒介するａ２ｂアデノシンリセプタ拮抗剤の同定および使用方法
US20200108069A1 (en) Treatment of Fibrotic Conditions
CN105106228B (zh) 用作TMEM16A离子通道激活剂的含人参皂苷Rb1的药物组合物
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására
US20240208961A1 (en) Eif4e inhibitors and uses thereof
SK8572003A3 (en) Histamine receptor antagonists
Song et al. TRPV2 Inhibition Prevents Right Ventricular Remodeling and Arrhythmia in Experimental Pulmonary Hypertension
US20140256738A1 (en) Use of selective dopamine d4 receptor agonists for treating sexual dysfunction
AU2007202036A1 (en) Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
CN119700753A (zh) 褪黑素和褪黑素受体激动剂在预防或治疗心脏瓣膜病中的应用
MXPA05010999A (es) Uso de derivados de esteroides para el tratamiento de enfermedades relacionadas con angiotensina ii por ejemplo trastornos cardiovasculares y proliferativos.
US11166940B2 (en) Treatment of cardiac disorders by blocking SK4 potassium channel
CN118121576A (zh) 美利曲辛在制备防治黑色素瘤药物中的应用
ZA200303093B (en) Selective dopamine D4 receptor agonists for treating sexual dysfunction.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2408791

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001261629

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001935542

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001935542

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001261629

Country of ref document: AU